Abiomed, Inc.
ABMD
NASDAQ254.56
Abiomed, Inc.
NASDAQ:ABMD
RECENT
PRICE
254.56
P/E
RATIO
83.19
(PEG:-2.10)
P/E RATIO
RELATIVE
TO S&P
4.30
DIV
YLD
0.00%
High:
Low:
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Legends
Stock price
1.35 Beta (1.0 Market)
0
0
0
0
0
0
0
0
0
% total return 07/22:
Stock
S&P
1y.
0
0
3y.
0
0
5y.
0
0
0
Percent shares traded:
0
0
0
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
Fiscal year
1.70
(1.15)
(0.48)
- -
1.87
(1.03)
(0.82)
- -
1.82
(1.26)
(1.01)
- -
2.10
(0.91)
(0.63)
- -
2.34
(0.52)
(0.25)
- -
2.72
(0.32)
(0.01)
- -
3.29
0.04
0.05
- -
4.04
0.38
0.60
- -
4.67
0.19
0.53
- -
5.67
2.80
0.94
- -
7.81
0.90
1.45
- -
10.30
1.21
1.50
- -
13.45
2.54
3.10
- -
17.13
5.77
4.64
- -
18.61
4.49
6.00
- -
18.78
5.00
4.90
- -
22.70
3.00
5.49
- -
Revenue per share
Earnings per share
Free Cash Flow per sh
Dividends per share
0.12
2.71
0.09
4.50
0.12
2.88
0.11
3.33
0.05
2.94
0.05
2.82
0.05
3.29
0.07
3.50
0.07
4.28
0.13
7.18
0.37
8.74
1.17
10.46
1.27
15.62
0.98
20.86
0.97
23.58
1.18
29.46
0.79
33.08
CAPEX per share
Book Value per share
26
27
32
35
37
37
38
39
39
41
42
43
44
45
45
45
45
Comm.Shares outs.(m)
(11.2)
(0.62)
- -
(12.4)
(0.72)
- -
(12.2)
(0.57)
- -
(9.4)
(0.13)
- -
(19.2)
(0.93)
- -
(46.7)
(2.87)
- -
515.7
34.68
- -
53.8
3.16
- -
146.1
8.05
- -
26.2
1.31
- -
114.9
5.18
- -
121.9
5.17
- -
132.4
5.30
- -
43.2
1.78
- -
51.9
1.37
- -
65.7
2.19
- -
95.0
4.91
- -
Avg. annual P/E ratio
P/E relative to S&P500
Avg. annual div. yield
Capital Structure (31/3/22 | Q4)
Total liabilities
$170 m.
Total assets
$1,673 m.
Long-term debt
- -
Cash and equiv.
$133 m.
Goodwill $77 m.
Retained earnings $965 m.
Common stock 46 m. shares
Market Capitalisation
$11,615 m. (as of 3/7/22)
101
(11.1)%
126
1.2%
158
10.5%
184
4.6%
230
12.4%
330
19.8%
445
20.2%
594
26.5%
769
29.2%
841
29.6%
848
27.1%
1,032
13.6%
Revenue (m)
Operating margin
4
(12)
4
1
3
15
3
7
3
114
3
38
6
52
11
112
14
259
20
203
24
226
28
137
Depreciation (m)
Net profit (m)
(8.2)%
(11.6)%
41.2%
1.2%
11.0%
9.5%
13.8%
4.0%
(295.2)%
49.4%
42.1%
11.6%
42.9%
11.7%
30.1%
18.9%
1.6%
33.7%
21.0%
24.1%
21.8%
26.6%
28.4%
13.2%
Income tax rate
Net profit margin
62
- -
105
88
- -
126
90
- -
137
88
- -
168
181
- -
292
242
- -
369
257
- -
452
410
- -
690
571
- -
937
504
- -
1,065
659
- -
1,330
838
- -
1,503
Working capital (m)
Long-term debt (m)
Equity (m)
(10.8)%
(8.3)%
(11.2)%
1.1%
1.7%
1.2%
10.5%
9.9%
11.0%
4.2%
4.2%
4.4%
38.0%
8.5%
39.0%
10.1%
15.5%
10.3%
10.8%
16.6%
11.5%
16.0%
20.4%
16.3%
27.3%
25.0%
27.6%
18.7%
21.1%
19.1%
16.5%
19.3%
17.0%
8.9%
11.4%
9.1%
ROIC
Return on capital
Return on equity
Working Capital
2020
2021
2022
Cash assets
443
483
384
Receivables
85
97
91
Inventory
90
81
94
Other
18
26
33
Current assets
636
788
976
Acc. Payable
33
35
35
Debt due
- -
- -
- -
Other
99
94
103
Current liab.
132
129
138
100.0%
- -
100.0%
- -
100.0%
(22.4)%
100.0%
64.9%
100.0%
2.1%
100.0%
- -
100.0%
- -
100.0%
- -
100.0%
- -
100.0%
- -
100.0%
31.3%
100.0%
5.1%
Plowback ratio
Div.&Repurch. to FCF
Abiomed, Inc. (US) started trading on July 3, 1987 (cik: 0000815094), operates in the Healthcare sector (Medical Devices industry), has 2,003 full-time employees, and is led by Mr. Michael Minogue. Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5, a percutaneous micro heart pump with integrated motor and sensors; and Impella CP, a device for use by interventional cardiologists to support patients in the cath lab, as well as by cardiac surgeons in the heart surgery suite. It also provides Impella 5.0, Impella LD, and Impella 5.5, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP, a percutaneous catheter-based axial flow pump; Impella SmartAssist platform that includes optical sensor technology for improved pump positioning and the use of algorithms that enable improved native heart assessment during the weaning process; Impella Connect, a cloud-based technology that enables secure and remote viewing of the automated impella controller for physicians and hospital staffs; and OXY-1 System, a portable external respiratory assistance device. In addition, the company is developing Impella ECP, a pump for blood flow of greater than three liters per minute; Impella XR Sheath, a sheath that expands and recoils allowing small bore access and closure with Impella heart pumps; Impella BTR, a percutaneous micro heart pump with integrated motors and sensors; and preCARDIA, a catheter-mounted superior vena cava therapy system designed to rapidly treat acutely decompensated heart failure. Abiomed, Inc. sells its products through direct sales and clinical support personnel in the Germany, France, United States, Japan, Europe, Canada, Latin America, the Asia-Pacific, and the Middle East. The company was founded in 1981 and is headquartered in Danvers, Massachusetts.
Annual rates
(avg rate of change)
Past
5 y.
Past
10 y.
Revenues
15.35%
23.83%
Cash flow
19.24%
36.27%
Earnings
20.23%
173.54%
Dividends
- -
- -
Book value
21.86%
31.67%
Insider trading
Type
Shares
Date
Plano Matthew T.
InKind
207
05/29/22
Plano Matthew T.
InKind
666
05/29/22
Plano Matthew T.
Award
1,500
05/29/22
Began Marc A
InKind
480
05/29/22
Began Marc A
InKind
976
05/29/22
Fiscal Year Ends
Quarterly Revenue (m)
Full fiscal year
I
II
III
IV
2020
208
205
222
207
841
2021
165
210
232
241
848
2022
253
248
261
270
1,032
Fiscal Year Ends
Earnings per share
Full fiscal year
I
II
III
IV
2020
1.97
0.29
1.53
0.70
4.49
2021
0.99
1.38
1.37
1.26
5.00
2022
(0.58)
1.25
1.01
1.33
3.00
Fiscal Year Ends
Quarterly dividends paid
Full fiscal year
I
II
III
IV
2020
- -
- -
- -
- -
- -
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -